Genomewide association study identifies a novel variant associated with tacrolimus trough concentration in Chinese renal transplant recipients.

Tacrolimus (TAC) is an immunosuppressant widely used in kidney transplantation. TAC displays considerable interindividual variability in pharmacokinetics (PKs). Genetic and clinical factors play important roles in TAC PKs. We enrolled a total of 251 Chinese renal transplant recipients and conducted a genomewide association study (GWAS), linkage disequilibrium (LD), and one-way analysis of variance (ANOVA) to find genetic variants affecting log-transformed TAC trough blood concentration/dose ratio (log[C /D]). In addition, we performed dual luciferase reporter gene assays and multivariate regression models to evaluate the effect of the genetic variants. The GWAS results showed that all 23 genomewide significant single-nucleotide polymorphisms (p < 5 × 10 ) were located on chromosome 7, including CYP3A53. LD, conditional association analysis, and one-way ANOVA showed that rs75125371 T > C independently influenced TAC log(C /D). Dual luciferase reporter gene assays indicated that rs75125371 minor allele (C) was significantly associated with increased normalized luciferase activity than the major allele (T) in the Huh7 cells (p = 1.2 × 10 ) and HepaRG cells (p = 0.0097). A model inclusive of age, sex, hematocrit, CYP3A53, and rs75125371 explained 37.34% variance in TAC C . These results suggest that rs75125371 T > C is a functional and population-specific variant affecting TAC C in Chinese renal transplant recipients.